window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : July 22, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

GLP-1

  • Biotech & Pharma Business,Manufacturing & Supply Chain,Pharmaceuticals and therapeutics,Research & Development

    Samsung Biologics to acquire PolyPeptide in $1.46bn deal

    Samsung Biologics has announced plans to acquire peptide CDMO PolyPeptide [...]

    July 21, 2026
  • Clinical & Regulatory,Drug Delivery & Formulation,Pharmaceuticals and therapeutics,Research & Development

    Rani reports positive Phase 1 data for oral obesity therapy RT-114

    Rani Therapeutics has reported positive initial Phase 1a data for [...]

    July 16, 2026
  • Clinical & Regulatory,Medical devices,Pharmaceuticals and therapeutics,Research & Development

    Revita maintains GLP-1 weight loss one year after treatment discontinuation in REMAIN-1 trial

    Fractyl Health has reported positive one-year data from the midpoint [...]

    July 16, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas

    Confo Therapeutics reports preclinical data for post-bariatric hypoglycaemia candidate at ENDO 2026

    Confo Therapeutics has presented preclinical data supporting the development of [...]

    June 16, 2026
  • Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas

    Verdiva Bio unveils obesity drug data ahead of planned clinical entry

    Verdiva Bio has reported new preclinical data for two obesity [...]

    June 9, 2026
  • Biotech & Pharma Business,Manufacturing & Supply Chain,Pharmaceuticals and therapeutics

    SGD Pharma highlights GLP-1 demand, supply chain pressure and sustainability focus at DCAT Week

    Interview with Carol Grassi Mircich, chief commercial marketing and innovation [...]

    May 5, 2026
  • Drug Discovery & Development,Manufacturing & Supply Chain,Pharmaceuticals and therapeutics

    Pharma firms localise GLP-1 supply chains as shortages and geopolitical risks grow

    Drugmakers are regionalising GLP-1 manufacturing as demand surges, shortages persist [...]

    May 5, 2026
  • Clinical & Regulatory,Digital & Data,Drug Discovery & Development,Genomics and sequencing,Therapeutic Areas

    23andMe study links genetics to GLP-1 weight loss outcomes and side effects

    This Nature-published study from the 23andMe Research Institute identifies genetic [...]

    May 5, 2026
  • Biotech & Pharma Business,Clinical & Regulatory,Drug Delivery & Formulation,Drug Discovery & Development,Therapeutic Areas

    Nanexa targets next-generation ‘fat jab’ with monthly semaglutide delivery platform

    Sweden-based Nanexa has reported preclinical data for a long-acting semaglutide [...]

    May 5, 2026
  • Clinical & Regulatory,Digital & Data,Drug Discovery & Development,Therapeutic Areas

    Breast cancer tops list of most-studied diseases for fifth consecutive year, Phesi analysis finds

    Breast cancer remained the world’s most studied disease for the [...]

    May 5, 2026
12Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Adneuris licenses Phase 3 pain therapy cebranopadol to Conba for Greater China
    Categories: Biotech & Pharma Business, Clinical & Regulatory, Drug Discovery & Development, Pharmaceuticals and therapeutics
  • Latent Labs opens lab-validated AI drug design platform to researchers worldwide
    Categories: Digital & Data, Drug Discovery & Development, Research & Development
  • PET imaging reveals widespread synaptic loss in schizophrenia
    Categories: Clinical & Regulatory, Research & Development, Therapeutic Areas
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top